Post operative infection and increased survival in osteosarcoma patients: Are they associated?

Annals of Surgical Oncology

Volumn 14, Issue 10, 2007, Pages 2887-2895

  Jeys, L M ^a   Grimer, R J ^a   Carter, S R ^a   Tillman, R M ^a   Abudu, A ^a  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE NECROSIS; BONE PROSTHESIS; BONE REMODELING; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PATIENT SELECTION; POSTOPERATIVE INFECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURGICAL PATIENT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIMB SALVAGE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTHESIS IMPLANTATION; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION;

EID: 34648820468     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9483-8     Document Type: Article

References (56)

1. Virkus WW, Marshall D, Enneking WF, Scarborough MT. The effect of contaminated surgical margins revisited. Clin Orthop Relat Res 2002;397:89-94
2. Rech A, Castro CG Jr, Mattei J, Gregianin L, Di Leone L, David A, Rivero LF, Tarrago R, Abreu A, Brunetto AL. Clinical features in osteosarcoma and prognostic implications. J Pediatr (Rio J) 2004; 80(1):65-70
3. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106(5):1154-61
4. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg Am 2002; 84-A(1):49-57
5. Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP, Grimer RJ. Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur J Cancer 2005; 41(18):2846-52. Epub 2005 Nov 7
6. Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer 1998; 82(5):851-9
7. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14(3):848-58
8. Raymond AK, Chawla SP, Carrasco CH, Ayala AG, Fanning CV, Grice B, Armen T, Plager C, Papadopoulos NE, Edeiken J. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987; 4(3):212-36
9. Juergens H, Kosloff C, Nirenberg A, Mehta BM, Huvos AG, Rosen G. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr. 1981; (56):221-6
10. Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, Forni C, Bertoni F, Versari M, Pignotti E. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002; 84(1):88-92
11. Rodriguez-Galindo C, Shah N, McCarville MB, Billups CA, Neel MN, Rao BN, Daw NC. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer 2004; 100(9):1928-35
12. Grimer RJ, Sommerville S, Warnock D, Carter S, Tillman R, Abudu A, Spooner D. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 2005; 41(4):578-83; Epub 2005 Jan 5
13. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12(2):423-31
14. Jeys LM, Grimer RJ, Carter SR, Tillman RM. Periprosthetic infection in patients treated for an orthopaedic oncological condition'. J Bone Joint Surg Am 2005; 87-A(4):842-9
15. Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, Straw RC, Withrow SJ. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol 2005; 12(12):1073-83.; Epub 2005 Oct 28
16. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. European Osteosarcoma Intergroup; The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001; 37(1):39-46
17. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38:163-170
18. Dupont WD, Plummer WD. Power and sample size calculations: a review and computer orogram. Controlled Clinical Trials 1990;11:116-28
19. Thrall DE, Withrow SJ, Powers BE, Straw RC, Page RL, Heidner GL, Richardson DC, Bissonnette KW, Betts CW, DeYoung DJ. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys 1990; 18(6):1351-7
20. Wiemann B, Starnes CO. Coley's toxins, tumour necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64(3): 529-64
21. American Cancer Society. Guide to complementary & alternative cancer methods. Atlanta: American Cancer Society Inc.; 2000
22. Shear MJ, Turner FC. Chemical treatment of tumours; isolation of hemorrhagic-producing fraction from Serratia marcescens (Bacillus prodigious) culture filtrate. J Natl Cancer Inst 1943; 4:81-7
23. Algire GH, Legallais FY, Park HD. Vascular reactions of normaland malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marcescens (Bacillus prodigious) culture filtrates. J Natl Cancer Inst 1947; 8:53-62
24. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 1975; 72:3666-70
25. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724-9
26. Hobohm U. Fever therapy revisited. Br J Cancer 2005; 92:421-5
27. Challis G, Stam H. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 1990; 29(5):545-50
28. Vermeire K, Schols D. Specific CD-4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003; 74(5):667-75
29. Sensenig DM, Rossi NP, Ehrenhaft JL. Pulmonary resection for bronchogenic carcinoma in geriatric patients. Ann Thorac Surg 1966; 2:508-13
30. Ruckdesche l JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972; 287:1013-7
31. Schantz SP, Skolnik EM, O'Neill JV. Improved survival associated with postoperative wound infection in laryngeal cancer: an analysis of its therapeutic implications. Otolaryngol Head Neck Surg 1980; 88:412-7
32. Koelmel K, Pfahlberg A, Mastrangelo G, Niin M, Botev I, Seebacher C, Schneider D, Lambert D, Shafir R, Kokoschka E, Kleeberg U, Henz B, Gefeller O. Infections and melanoma risk: results of a multicenter EORTC case study. Melanoma Res 1999; 9:511-519
33. Krone B, Kolmel KF, Grange JM, Mastrangelo G, Hez BM, Botev IN, Niin M, Seebacher C, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A. Impact of vaccinations and infectious diseases on the risk of melanoma - evaluation of an EORTC case control study. Eur J Cancer. 2004; 39(16):2372-8
34. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:1689-94
35. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. The palliative value of tumour necrosis alpha based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer. 2006; 106(1):156-62
36. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. TNF-based isolated limb perfusion of unresectable extremity desmoid tumours. Eur J Surg Oncol 2005; 31(8):912-8
37. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724-9
38. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45:491-503
39. Hibbs Jr JB, Lambert Jr LH, Remington JS. Resistance to murine tumours conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis 1971; 124:587-92
40. Hibbs Jr JB, Lambert Jr LH, Remington JS. Control of carcinogenesis: a possible role for the activated macrophage. Science 1972; 177:998-1000
41. Hibbs Jr JB, Lambert Jr LH, Remington JS. Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol 1972; 235:48-50
42. Hibbs Jr JB. Infection and nitric oxide. J Infect Dis 2002; 185:S9-S17
43. North RJ, Kirstein DP. T-cell-mediated concomitant immunity to syngeneic tumours. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumours and bacterial parasites. J Exp Med 1977; 145:275-92
44. Youdim S, Sharman M. Resistance to tumor growth mediated by Listeria monocytogenes: collaborative and suppressive macrophagelymphocyte interactions in vitro. J Immunol 1976; 117:1860-5
45. Keller R, Keist R, Leist TP, van der Meide PH. Resistance to a non-immunogenic tumor, induced by Corynebacterium parvum or Listeria monocytogenes, is abrogated by anti-interferon γ. Int J Cancer 1990; 46:687-90
46. Hunter CA, Yu D, Gee M, Ngo C, Sevignani C, Goldscmidt M. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumours during acute toxoplasmosis. J Immunol 2001; 166:5878-81
47. Thomas-Tikhonenko A, Hunter CA. Infection and cancer: the common vein Cytokine Growth Factor Rev. 2003; 14:67-77
48. Mori K, Redini F, Gouin F, Cherrier B, Heymann D. Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep 2006; 15(3):693-700
49. Muller R, Sigbjorn S, Bauer H, Saeter G, Strander H. Interferon-a as the only adjuvant treatment in high-grade Osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncologica 2005; 44:475-80
50. Inaba H, Glibetic M, Buck S, Ravindranath Y, Kaplan J. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up regulating Fas receptors and caspase-8. Pediatr Blood Cancer 2004; 43(7):729-36
51. Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, Hale J, Douglas C, Pagonis C, Campbell B, Alvarez P, Halbert G, Durrant LG. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005; 92(8):1358-65
52. Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2006; 2(3):333-43. Review
53. Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 2006; 6(2):123-33. Review
54. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML,Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23(9):2004-11
55. Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm 1999; 14(2):121-8
56. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995; 1(12):1595-601